Special Issue "Immune Response in Human Cancers"

Dear Colleagues,

Cancer immunotherapy provided revolutionary approaches to treating cancer patients, along with other cancer treatments of surgery, radiation, chemotherapy, and targeted therapies. Although it brings success and hopes to curing cancer, it is urgent to develop more strategies to overcome immunotherapy resistance mechanisms. Based on current types of immunotherapies, we would like to update in following aspects, but not restricted to immune checkpoint blockades, such as PD-1, PD-L1, and CTLA-4 inhibitors; adoptive cell therapies, for example, tumor-infiltrating lymphocyte therapy, CAT T-cell therapy, and natural killer cell therapy; monoclonal antibodies; oncolytic virus therapy; cancer vaccine; immune system modulators to retrospect the progress of immunotherapy. The general ideas are activating exhausted T-cells to function better, helping immune cells to recognize the cancer cells, attracting immune cells to infiltrate the tumor microenvironment. Immunotherapy also could cause side effects from the overstimulated or misdirected immune response, ranging from mild or moderate to severe to life-threatening. So, it is extremely important for patients to be monitored for any unusual symptoms.

This Special Issue of immune responses in cancer compiles a series of articles, presenting and reviewing the latest and novel strategies to focus on several important aspects of the most recent advancement in cancer therapy.

Dr. Peng Liao
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• immunotherapy